Formulation exports boost Zydus Cadila's revenues in Q3
This article was originally published in Scrip
Executive Summary
Zydus Cadila has reported a 31% increase in revenues to Rs7.59 billion ($155.5 million) for the third quarter ended December 2008, led by a surge in formulations exports. Net profits rose by 17% to Rs610 million. The profits are after providing for an exchange rate fluctuation loss of Rs110 million on conversion of foreign currency loans during the quarter, as against a gain of Rs60 million during the same period last year. Formulation exports rose by 61%.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.